Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Psychiatric disorders – page 6

  • 546 clinical trials
  • 252 recruiting
  • 147 conditions
  • 26 countries

Conditions in this area

147 conditions with trials, the busiest first

Dementia Alzheimer's type87Major depression57Schizophrenia39Depression35Narcolepsy19Cognitive disorder18Bipolar disorder16Autism spectrum disorder15Insomnia15Post-traumatic stress disorder14Psychotic disorder14Drug use disorder13Alcohol use disorder12Attention deficit hyperactivity disorder9Dementia9Obstructive sleep apnoea syndrome9Brain injury8Irritable bowel syndrome8Phenylketonuria8Bipolar I disorder7Drug dependence7Hypersomnia7Lennox-Gastaut syndrome7Anorexia nervosa6+123

Clinical trials in Psychiatric disorders

546 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

546 clinical trials

Depression

Recruiting

Testing dehydroepiandrosterone combined with standard antidepressants for patients with treatment-resistant depression

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lactose Monohydrate
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Neurodevelopmental disorder

Recruiting

A Study of Gene Replacement Therapy for Children with CTNNB1 Syndrome Using Adeno-Associated Viral Vector Serotype 9 Containing the Human CTNNB1 Gene

InvestigationalNo placebo
Countries:SloveniaSlovenia
  • Participants:0–17 years
  • Substances:ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE 9 CONTAINING THE HUMAN CTNNB1 GENE
  • Sponsor:Fundacija CTNNB1 Ustanova Za Raziskave Na Podrocju Genske Terapije

Major depression

Recruiting

A Study of Brexanolone Caprilcerbate for Adults with Major Depressive Disorder With or Without Anxious Distress

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Seaport Therapeutics Inc.

Dementia with Lewy bodies

Recruiting

A Study of ACP-204 Tartrate for Adults With Lewy Body Dementia Psychosis

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Acp-204 Tartrate
  • Sponsor:Acadia Pharmaceuticals Inc.

Dementia with Lewy bodies

Recruiting

A Study Testing ACP-204 Tartrate Compared to Placebo for Adults with Lewy Body Dementia Psychosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Acp-204 Tartrate
  • Sponsor:Acadia Pharmaceuticals Inc.

Dementia of the Alzheimer's type with delusions

Recruiting

A Study of Fesoterodine and 5-[(1R,5R)-3-Azabicyclo[3.

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE
  • Sponsor:Maplight Therapeutics Inc.

Dementia Alzheimer's type

Recruiting

Study of KarXT (trospium chloride and xanomeline tartrate) and KarX-EC (xanomeline tartrate) for cognitive impairment in mild to moderate Alzheimer's disease

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Dementia Alzheimer's type

Recruiting

Study of xanomeline tartrate and trospium chloride combination for cognitive impairment in people with mild to moderate Alzheimer's disease

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Dementia Alzheimer's type

Recruiting

Study of xanomeline tartrate and trospium chloride combination for treating agitation in Alzheimer's disease patients

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Major depression

Recruiting

Study of D-cycloserine with theta-burst brain stimulation for adults with major depressive disorder

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Sponsor:Region Uppsala

Epileptic encephalopathy

Recruiting

Study of Elsunersen in Children with SCN2A Developmental and Epileptic Encephalopathy to Reduce Seizures

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:5'-MOEMC-(SP)-MOEMC-(P)-MOEA-(P)-MOEMC-(P)-MOEG-(P)-MOEA-(P)-DMC-(SP)-DA-(SP)-DT-(SP)-DA-(SP)-DT-(SP)-DT-(SP)-DT-(SP)-DT-(SP)-DT-(SP)-DMC-(SP)-MOET-(P)-MOEA-(SP)-MOEMC-(SP)-MOEA 3'
  • Sponsor:Praxis Precision Medicines Inc.

Neurodevelopmental disorder

Recruiting

Study of levodopa and carbidopa treatment for patients with neurodevelopmental disorder caused by CTNNB1 gene mutation

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Carbidopa
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Substances studied in this area

The therapies tested most often in Psychiatric disorders trials.

Sodium Chloride25 clinical trialsTrospium Chloride17 clinical trialsXanomeline Tartrate16 clinical trialsCannabidiol15 clinical trialsDry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol14 clinical trialsFlorquinitau (18F)14 clinical trialsOxytocin13 clinical trialsAripiprazole12 clinical trialsFlorbetaben (18F)12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.